Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 950 of 6351
-
Can an antidepressant calm Chemotherapy's nerve pain?
Symptom relief Recruiting nowThe study is to evaluate the efficacy and safety of duloxetine in Chinese solid tumor patients with taxanes-induced painful peripheral neuropathy. Duloxetine will be given to patients who have grade 1 or higher sensory neuropathy according to the NCI Common Terminology Criteria f…
Phase 2 • Sponsor: Yan Yang, MD, Ph.D • Aim: Symptom relief
Last updated Sep 10, 2026 00:00 UTC
-
New drug nipocalimab aims to tame lupus flares
Disease control CompletedThe purpose of this study is to evaluate the efficacy of nipocalimab versus placebo in participants with active systemic lupus erythematosus (SLE).
Phase 2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Off-the-Shelf cell therapy takes on tough blood cancers
Disease control OngoingThis is a single arm, open-label, multi-center, Phase 1 study to determine the safety and tolerability of an experimental therapy called NKX019 (allogeneic CAR NK cells targeting CD19) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (…
Phase 1 • Sponsor: Nkarta, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Double-Dose precision: new combo radiation aims to shrink prostate tumors faster
Disease control Recruiting nowThis phase II trial investigates the effect of high dose-rate brachytherapy and stereotactic body radiotherapy in treating patients with prostate adenocarcinoma. Brachytherapy, also known as internal radiation therapy, uses radioactive material placed directly into or near a tumo…
Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New proton beam trial aims to spare healthy tissue in kids with kidney cancer
Disease control Recruiting nowParticipants are being asked to take part in this clinical trial, a type of research study, because the participants have a Wilms Tumor cancer. Primary Objectives To determine whether delivery of proton beam radiation to a conformal reduced target volume in the flank allows nor…
Phase 2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Freezing away heart flutters: new study tests Long-Term control of persistent AF
Disease control OngoingThe STOP Persistent AF Post Approval Study (PAS) is a prospective, global, multicenter, observational trial.
Sponsor: Medtronic Cardiac Ablation Solutions • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New hope for tough lung cancer: experimental combos tested in 110 patients
Disease control OngoingThis study is a rolling arm study of investigational agents as monotherapy or in combination with pembrolizumab in participants with anti-programmed cell death 1 (PD-1)/ programmed cell death ligand 1 (PD-L1) refractory ES-SCLC in need of second-line treatment. This study will ha…
Phase 1/2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Tiny eye implant could free glaucoma patients from daily drops
Disease control OngoingEvaluate the safety and effectiveness of iSTAR Medical's MINIject™ implant for lowering intraocular pressure (IOP) in subjects with primary open-angle glaucoma.
Sponsor: iSTAR Medical • Aim: Disease control
Last updated Jun 26, 2026 16:47 UTC
-
New drug cocktail aims to boost remission in rare blood cancer
Disease control OngoingIn Waldenström macroglobulinemia (WM) chemotherapy induces only low CR/VGPR (Complete Remission/ Very Good Partial Response) rates and responses of short duration compared to other indolent lymphomas. Thus, innovative approaches are needed which combine excellent activity and tol…
Phase 2 • Sponsor: Christian Buske • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Immunotherapy cocktail shows promise in shrinking esophageal tumors before surgery
Disease control CompletedThe purpose of this study is to evaluate the pathological complete response (pCR) in participants receiving tislelizumab plus chemotherapy/chemoradiotherapy as neoadjuvant treatment.
Phase 2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
App-based symptom tracking may cut hospital visits for advanced cancer patients
Symptom relief Recruiting nowPancreatic and biliary tract cancer are ones of the leading causes of cancer-related deaths. During the course of illness, these patients often experience marked physical suffering, psychological distress and frequent unplanned resource-demanding hospitalized care. Patients with …
Sponsor: Inna Chen, MD • Aim: Symptom relief
Last updated Sep 04, 2026 00:00 UTC
-
Can a new IV antiviral tame two stubborn viruses?
Disease control CompletedThe purpose of this study is to determine the safety and tolerability of intravenous (IV) brincidofovir (BCV; SyB V-1901) 0.2 mg/kg, 0.3 mg/kg or 0.4 mg/kg dosed twice weekly (BIW) or 0.4 mg/kg dosed once weekly (QW) for 4 weeks in subjects with AdV, and IV BCV in subjects with C…
Phase 2 • Sponsor: SymBio Pharmaceuticals • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Gene Therapy's lasting promise: can one infusion safely control fabry disease for years?
Disease control OngoingLong-term follow-up of subjects who received ST-920 in a previous trial (ST-920-201) and completed at least 52 weeks post-infusion follow-up in their primary protocol. Enrolled subjects will be followed for a total of up to 5 years following ST-920 infusion.
Sponsor: Sangamo Therapeutics • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
A psychedelic compound may lift mood in Parkinson's, and a trial puts it to the test
Symptom relief CompletedThe purpose of this study is to determine the safety, tolerability, and feasibility of psilocybin therapy for depression and anxiety in people with Parkinson's disease.
Phase 2 • Sponsor: Joshua Woolley, MD, PhD • Aim: Symptom relief
Last updated Sep 05, 2026 00:00 UTC
-
New drug could save lives from shock after severe bleeding
Disease control Recruiting nowThis is a prospective, multi-centric, open-labeled, phase-IV clinical study to evaluate the safety and efficacy of centhaquine citrate (LYFAQUIN™), a first-in-class drug for treating hypovolemic shock, a life-threatening condition caused by severe blood or fluid loss. Centhaquine…
Phase 4 • Sponsor: Pharmazz, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Brain zap tailored to each patient could tame tough OCD
Disease control Recruiting nowDeep brain stimulation (DBS) is an effective treatment for people suffering from severe obsessive-compulsive disorder (OCD) whose symptoms have failed to improve after years and multiple methods of intervention. An effective DBS target for OCD is the anterior limb of the internal…
Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for kids with severe colitis: oral drug shows promise
Disease control OngoingThis study, A3921210 is designed to evaluate the efficacy, safety and pharmacokinetics (PK) of tofacitinib in pediatric participants with moderately to severely active UC. In the US and EU, patients with prior TNFi failure or intolerance will be enrolled. Outside of the US or EU,…
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New pill shows promise for rare tumors in Mid-Stage trial
Disease control Recruiting nowThis is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) disease-associated tumors, advanced wt (wild-type) gastrointestinal s…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Triple-Drug attack shows promise against tough prostate cancer
Disease control Recruiting nowThis is a phase I/II study investigating the combination of 225Ac-J591 (a drug that can deliver radiation to prostate cancer cells) with pembrolizumab (immunotherapy, a drug that increases the immune system's ability to destroy cancer cells). This study will assess whether 225Ac-…
Phase 1/2 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New 'See and Treat' approach targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThe aim of this study is to determine the safety and efficacy of 67Cu-SAR-bisPSMA in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
Phase 1/2 • Sponsor: Clarity Pharmaceuticals Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC